课题基金 / 基金详情

DISSIMILAR IMMUNOGENICITIES OF ELA AND E7 ONCOPROTEINS

DISSIMILAR IMMUNOGENICITIES OF ELA AND E7 ONCOPROTEINS
ELA 和 E7 癌蛋白的免疫原性不同
批准号:
6376598
负责人:
John Michael Routes
金额:
$24.58万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-01 至 2003-06-30

项目摘要

项目成果

John Michael Routes的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of the project is to use the MCA-102 model system to elucidate the immunologic mechanisms involved in the rejection of E1A- but not E7-expressing tumor cells, genetically define the components of ElA that are required to induce robust cellular immunity, and further characterize the molecular basis by which ElA but not E7 induces a vigorous cellular immune response in two specific aims. Specific Aim 1: Elucidate the key immunologic mechanisms involved in the rejection of tumor cells expressing ElA but not E7. Specifically they will determine the interrelationship and function of NK cells, T cells, perforin- and Fas-mediated lysis and the cytokines, IL-12 and IFNg, in the rejection of E1A- but not E7-expressing tumor cells. Specific Aim 2: Define the molecular mechanisms by which E1A-p300 binding and ElA- exon 2 expression activate the NK cell response, thereby triggering a robust cellular immune response against E1A-expressing tumor cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autoantibody production and regulatory T cells
  • 批准号:
    8513699
  • 项目类别:
  • 资助金额:
    $37.83万
  • 财政年份:
    2012
  • 负责人:
    John Michael Routes
  • 依托单位:
Anti-tumorigenic Activity of Adenovirus E1A
  • 批准号:
    7845313
  • 项目类别:
  • 资助金额:
    $2.2万
  • 财政年份:
    2009
  • 负责人:
    John Michael Routes
  • 依托单位:
Lymphoproliferative Disorders in Primary Immunodeficiencies
  • 批准号:
    8206706
  • 项目类别:
  • 资助金额:
    $31.44万
  • 财政年份:
    2008
  • 负责人:
    John Michael Routes
  • 依托单位:
Lymphoproliferative Disorders in Primary Immunodeficiencies
  • 批准号:
    8011454
  • 项目类别:
  • 资助金额:
    $28.29万
  • 财政年份:
    2008
  • 负责人:
    John Michael Routes
  • 依托单位: